Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 19,549

Document Document Title
WO/2018/013508A1
Described herein are substituted aminothiazoles, compositions comprising same; and methods of making and using same.  
WO/2018/011747A1
The present invention provides compounds which are modulators of RORγ and their use for the treatment of diseases or conditions mediated by RORγ. Further, the present invention relates to processes of preparing such compounds, their ta...  
WO/2018/008989A1
The present invention provides a benzo[d]thiazole derivative or a pharmaceutically acceptable salt thereof, a method for producing the same, and a pharmaceutical composition including the same. The benzo[d]thiazole derivative or the phar...  
WO/2018/005416A1
A dual curable thiol-ene composition comprising a polythiol, an unsaturated compound, a photoinitiator, an organic hydroperoxide (thermal initiator) and optionally a nitrogen-containing base, such as e.g. an N-heterocyclic compound (toge...  
WO/2017/219083A1
The present invention relates to novel compounds which active HIV expression in latently infected cells. More particularly, the invention relates to pharmaceutical compositions comprising the novel compounds and their use in activating H...  
WO/2017/223491A1
Provided is a method of inhibiting viral replication, including contacting one or more cells that has been infected or contacted with a flavivirus with an effective amount of niclosamide, temoporfin, nitazoxanide, tizoxanide, erythrosin ...  
WO/2017/215552A1
Compounds, pharmaceutical compositions, and methods for treatment of microbial infections are provided. The compounds can potentiate the therapeutic effects of one or more antimicrobial agents when co-administered. The compounds have ant...  
WO/2017/214005A1
The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicament.  
WO/2017/206955A1
Provided are applications of a thiazole derivative in treating virus infection and in the preparation of drugs for treating virus infection. Specifically, provided are applications of a compound represented by formula (I) and a pharmaceu...  
WO/2017/210696A1
Embodiments relate to pharmaceutical compositions, comprising one or more beta-3 adrenoceptor agonists that are useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder, prostate disorders and met...  
WO/2017/207362A1
Compounds of the formula (I): wherein the substituents are as defined in claim 1, useful as pesticides, and especially fungicides.  
WO/2017/202376A1
A sulfamide compound and a use thereof in preparing pain killers, which specifically relates to compounds as shown in formula (I) and formula (II), tautomers thereof or pharmaceutically acceptable salts thereof.  
WO/2017/198647A1
The invention relates to antibacterial compounds of formula (I) wherein the group M and R1 are as defined in the claims, and salts thereof.  
WO/2017/199862A1
The purpose of the present invention is to provide a method for manufacturing a high-purity polymerizable compound in an industrially advantageous manner. The manufacturing method according to the present invention is a method for manufa...  
WO/2017/198178A1
A thiazole derivative serving as a DHODH inhibitor, and applications thereof. The present invention specifically relates to a compound represented by formula I, a pharmaceutical composition containing the compound represented by formula ...  
WO/2017/201502A1
Disclosed are methods of treating cancer using a combination of an immunotherapeutic agent, such as, for example, a PD-1, PD-L1 or CTLA-4 checkpoint inhibitor, and a glutamate modulating agent such as riluzole or trigriluzole. Pharmaceut...  
WO/2017/201501A1
Disclosed are methods of treating cancer using a combination of an immunotherapeutic agent, such as, for example, a PD-1, PD-L1 or CTLA-4 checkpoint inhibitor, and a glutamate modulating agent such as riluzole or trigriluzole. Pharmaceut...  
WO/2017/193757A1
Provided are a water-soluble Epothilone derivative represented by formula (I), a preparation method therefor and an intermediate thereof, and an application thereof in preparation of drugs for inhibiting growth of tumor cells.  
WO/2017/191000A1
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...  
WO/2017/193041A1
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.  
WO/2017/193063A1
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.  
WO/2017/188485A1
Provided is a compound represented by formula (A-V), wherein Y represents a p-valent anion; R1A to R8A each independently represent a hydrogen atom or an alkyl group having 1-10 carbon atoms; R9A and R10A each independently represent a h...  
WO/2017/184624A1
In one aspect, compounds of Formulae (I) and (II), or pharmaceutically acceptable salts thereof, are featured; Formula (I), Formula (II) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formulae (I) and (II) ...  
WO/2017/181585A1
The present invention relates to the technical field of medicine, and specifically relates to a PUMA inhibitor, a method for preparation thereof, and a use thereof. The PUMA inhibitor is the compound as shown in (I) or a pharmaceutically...  
WO/2017/184604A1
In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured, or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.  
WO/2017/183625A1
[Problem] To provide an organic electroluminescence element comprising, in order to improve the element characteristics of the organic EL element, in particular, so as to absorb 400-410 nm wavelength sunlight and not have effects on an i...  
WO/2017/183723A1
The present invention addresses the problem of providing a novel compound having a strong opening action with respect to KCNQ 2-5 channels. Provided is a compound represented by the general formula (I) (in the formula, the definitions of...  
WO/2017/178174A1
The present invention relates compounds useful and their use for treating cholestatic and fibrotic diseases.  
WO/2017/179883A1
The present specification relates to a compound expressed by the first chemical formula, and to an organic electronic element comprising same.  
WO/2017/175986A1
The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound of the present disclosure provides an organic electroluminesce...  
WO/2017/174640A1
The invention relates to novel compounds of the Formula (I), to a process for their preparation and to their use as medicaments, in particular as antiviral medicaments.  
WO/2017/169839A1
The present invention provides a novel method for producing a 2-hydrazinobenzothiazole derivative. The present invention also provides: a method for producing a compound using the 2-hydrazinobenzothiazole derivative obtained by said prod...  
WO/2017/173313A1
Pateamine A derivatives, pharmaceutical compositions that include the derivatives, and methods for treating chronic lymphocytic leukemia using the derivatives.  
WO/2017/165204A1
Disclosed are compounds of Formula A-1, or a salt thereof: Formula A-1, where J, K, Q and R1 are as defined herein, which compounds have properties for inhibiting sodium ion channels found in peripheral and sympathetic neurons. Also desc...  
WO/2017/165256A1
The present disclosure relates to compounds of formula (I) that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly ...  
WO/2017/161524A1
Provided is a pyruvate dehydrogenase kinase inhibitor and an application therefor. Specifically provided is a compound Ra-S-S-Rb of formula X or a pharmaceutically acceptable salt thereof, the compound having excellent inhibition of pyru...  
WO/2017/160922A1
Disclosed herein are compounds of Formula (I), methods of synthesizing compounds of Formula (I), and methods of using compounds of Formula (I) as an analgesic.  
WO/2017/161183A1
There are provided, inter alia, compositions and methods for covalently binding peptides to proteins.  
WO/2017/160930A1
Disclosed herein are compounds of Formula (I), methods of synthesizing compounds of Formula (I), and methods of using compounds of Formula (I) as an analgesic.  
WO/2017/155910A1
A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclo...  
WO/2017/155092A1
The present invention provides a composition for controlling a plant disease comprising a tetrazolinone compound represented by formula (1) wherein X1 represents a halogen atom etc., and X2 represents a C1-C3 alkyl group etc., and at lea...  
WO/2017/154588A1
The present invention provides a novel method for producing a compound having an ester group, and a derivative produced using the compound as a synthesis intermediate. Also provided are a polymerizable composition containing a compound o...  
WO/2017/149332A1
The subject of the present invention is the cocrystal form of (R)-2-(2-aminothiazol-4-yl)-4'- {2-[(2-hydroxy-2-phenyl)ethylamino]ethyl}acetamide (mirabegron) of formula (1) and halide salt of an alkaline earth metal or halide salt of a d...  
WO/2017/147316A1
The invention provides synthetic processes and synthetic intermediates that can be used to prepare a compound of formula (I): or a salt thereof.  
WO/2017/141049A1
Provided are compounds of the Formula (I), or a pharmaceutically acceptable salt thereof, wherein W, X, Y, Z, x, R1, R2, R3, x and n are defined in the specification. The compounds are inhibitors of lysyl oxidase (LOX) and lysyl oxidase-...  
WO/2017/137784A1
The object of the present invention relates to a method for the production of formula 1 (R)-2- (2-aminothiazole-4-yl)-4'-[2-[(2-hydroxy-2-phenyl)ethylamino ]ethyl]acetanilide (mirabegron) and formula 1c mirabegron monohydrochloride, as w...  
WO/2017/134547A1
The present invention is directed to novel cytotoxic tubulysin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.  
WO/2017/136375A1
This invention relates to deuterated forms of morpholinobenzo[d]thiazol-2-yl)-4-methylpiperidine-1-carboxa mide compounds, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of ...  
WO/2017/135786A1
The present invention relates to a novel amide compound usefully available for the prevention or treatment of a bone disease and the use thereof.  
WO/2017/132158A1
The invention provides a crystalline form of the compound of formula (Ia), methods for making the crystalline form of the compound of formula (Ia), and therapeutic methods for the use of the crystal line form of the compound of formula (...  

Matches 1 - 50 out of 19,549